Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Recurrence 1Neoplasms 1Ependymoma 1Disease Progression 1Diffuse Intrinsic Pontine Glioma 1

Interventions

Temozolomide 4Surgical Procedures, Operative 2Radiotherapy 2Magnetic Resonance Spectroscopy 2Gadolinium DTPA 2Filgrastim 2Erlotinib Hydrochloride 2Congresses as Topic 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2vitespin 1sargramostim 1picropodophyllin 1marizomib 1imetelstat 1gadobutrol 1gadobenic acid 1fluorodopa F 18 1bempegaldesleukin 1antineoplaston AS 2-1 1antineoplaston A10 1Yoga 1Transurethral Resection of Bladder 1Topotecan 1Thiotepa 1Ritonavir 1Radiation 1Peripheral Blood Stem Cell Transplantation 1Perfusion Magnetic Resonance Imaging 1O(6)-benzylguanine 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Ependymoma × marizomib × Clear all
NCT03727841 2022-07-27

Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
4 enrolled 13 charts

Ependymoma, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡